|
1
|
Rousseau A, Mokhtari K and Duyckaerts C:
The 2007 WHO classification of tumors of the central nervous
system-what has changed? Curr Opin Neurol. 21(720)2008.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Chargari C, Feuvret Lc, Bauduceau O,
Ricard D, Cuenca X, Delattre JY and Mazeron JJ: Treatment of
elderly patients with glioblastoma: From clinical evidence to
molecular highlights. Cancer Treat Rev. 38:988–995. 2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Franceschi E, Ermani M, Bartolini S,
Bartolotti M, Poggi R, Tallini G, Marucci G, Fioravanti A, Tosoni
A, Agati R, et al: Post progression survival in glioblastoma: Where
are we? J Neurooncol. 121:399–404. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Radin DP, Purcell R and Lippa AS:
Oncolytic properties of ampakines in vitro. Anticancer Res.
38:265–269. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Piascik MT and Perez DM: Alpha1-adrenergic
receptors: New insights and directions. J Pharmacol Exp Ther.
298:403–410. 2001.PubMed/NCBI
|
|
7
|
Salomonsson M, Oker M, Kim S, Zhang H,
Faber JE and Arendshorst WJ: Alpha1-adrenoceptor subtypes on rat
afferent arterioles assessed by radioligand binding and RT-PCR. Am
J Physiol Renal Physiol. 281:F172–F178. 2001.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kyprianou N, Litvak JP, Borkowski A,
Alexander R and Jacobs SC: Induction of prostate apoptosis by
doxazosin in benign prostatic hyperplasia. J Urol. 159:1810–1815.
1998.PubMed/NCBI
|
|
9
|
Cal C, Uslu R, Gunaydin G, Ozyurt C and
Omay SB: Doxazos in: A new cytotoxic agent for prostate cancer? BJU
Int. 85:672–675. 2000.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kyprianou N and Benning CM: Suppression of
human prostate cancer cell growth by alpha1-adrenoceptor
antagonists doxazosin and terazosin via induction of apoptosis.
Cancer Res. 60(4550)2000.PubMed/NCBI
|
|
11
|
Benning CM and Kyprianou N:
Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate
cancer cell apoptosis via an alpha1-adrenoceptor-independent
action. Cancer Res. 62:597–602. 2002.PubMed/NCBI
|
|
12
|
Partin JV, Anglin IE and Kyprianou N:
Quinazoline-based α1-adrenoceptor antagonists induce prostate
cancer cell apoptosis via TGF-β signalling and IκBα induction. Br J
Cancer. 88:1615–1621. 2003.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Cuellar DC, Rhee J and Kyprianou N:
Alpha1-adrenoceptor antagonists radiosensitize prostate cancer
cells via apoptosis induction. Anticancer Res. 22:1673–1679.
2002.PubMed/NCBI
|
|
14
|
Hui H, Fernando MA and Heaney AP: The
alpha1-adrenergic receptor antagonist doxazosin inhibits EGFR and
NF-kappaB signalling to induce breast cancer cell apoptosis. Eur J
Cancer. 44:160–166. 2008.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Siddiqui EJ, Shabbir M, Thompson CS,
Mumtaz FH and Mikhailidis DP: Growth inhibitory effect of doxazosin
on prostate and bladder cancer cells. Is the serotonin receptor
pathway involved? Anticancer Res. 25(4281)2005.PubMed/NCBI
|
|
16
|
Masachika E, Kanno T, Nakano T, Gotoh A
and Nishizaki T: Naftopidil induces apoptosis in malignant
mesothelioma cell lines independently of alpha1-adrenoceptor
blocking. Anticancer Res. 33:887–894. 2013.PubMed/NCBI
|
|
17
|
Park MS, Kim BR, Dong SM, Lee SH, Kim DY
and Rho SB: The antihypertension drug doxazosin inhibits tumor
growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling
and VEGF and HIF-1α expression. Oncotarget. 5:4935–4944.
2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hu ZW, Shi XY, Lin RZ, Chen J and Hoffman
BB: alpha1-Adrenergic receptor stimulation of mitogenesis in human
vascular smooth muscle cells: Role of tyrosine protein kinases and
calcium in activation of mitogen-activated protein kinase. J
Pharmacol Exp Ther. 290:28–37. 1999.PubMed/NCBI
|
|
19
|
Assad Kahn S, Costa SL, Gholamin S, Nitta
RT, Dubois LG, Fève M, Zeniou M, Coelho PL, El-Habr E, Cadusseau J,
et al: The anti-hypertensive drug prazosin inhibits glioblastoma
growth via the PKCδ-dependent inhibition of the AKT pathway. EMBO
Mol Med. 8:511–526. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Oh SJ, Yang JI, Kim O, Ahn EJ, Kang WD,
Lee JH, Moon KS, Lee KH and Cho D: Human U87 glioblastoma cells
with stemness features display enhanced sensitivity to natural
killer cell cytotoxicity through altered expression of NKG2D
ligand. Cancer Cell Int. 17(22)2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wang J, Liu K, Wang XF and Sun DJ: Juglone
reduces growth and migration of U251 glioblastoma cells and
disrupts angiogenesis. Oncol Rep. 38:1959–1966. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Liu Z, Wang F, Zhou ZW, Xia HC, Wang XY,
Yang YX, He ZX, Sun T and Zhou SF: Alisertib induces
G2/M arrest, apoptosis, and autophagy via PI3K/Akt/mTOR-
and p38 MAPK-mediated pathways in human glioblastoma cells. Am J
Transl Res. 9:845–873. 2017.PubMed/NCBI
|
|
23
|
Iżycka-Świeszewska E, Drożyńska E, Rzepko
R, Kobierska-Gulida G, Grajkowska W, Perek D and Balcerska A:
Analysis of PI3K/AKT/MTOR signalling pathway in high risk
neuroblastic tumours. Pol J Pathol. 61:192–198. 2010.PubMed/NCBI
|
|
24
|
Horvath S, Zhang B, Carlson M, Lu KV, Zhu
S, Felciano RM, Laurance MF, Zhao W, Qi S, Chen Z, et al: Analysis
of oncogenic signaling networks in glioblastoma identifies ASPM as
a molecular target. Proc Natl Acad Sci USA. 103:17402–17407.
2006.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Davis ME: Glioblastoma: Overview of
disease and treatment. Clin J Oncol Nurs. 20 (Suppl):S2–S8.
2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
D'Alessandro G, Catalano M, Sciaccaluga M,
Chece G, Cipriani R, Rosito M, Grimaldi A, Lauro C, Cantore G,
Santoro A, et al: KCa3.1 channels are involved in the infiltrative
behavior of glioblastoma in vivo. Cell Death Dis.
4(e773)2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wirth T, Samaranayake H, Pikkarainen J,
Määttä AM and Yläherttuala S: Clinical trials for glioblastoma
multiforme using adenoviral vectors. Curr Opin Mol Ther.
11:485–492. 2009.PubMed/NCBI
|
|
28
|
Jakola AS, Gulati S, Weber C, Unsgård G
and Solheim O: Postoperative deterioration in health related
quality of life as predictor for survival in patients with
glioblastoma: A prospective study. PLoS One.
6(e28592)2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Mcgirt MJ, Mukherjee D, Chaichana KL, Than
KD, Weingart JD and Quinones-Hinojosa A: Association of surgically
acquired motor and language deficits on overall survival after
resection of glioblastoma multiforme. Neurosurgery. 65:463–470.
2009.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Juillerat-Jeanneret L: The targeted
delivery of cancer drugs across the blood-brain barrier: Chemical
modifications of drugs or drug-nanoparticles? Drug Discov Today.
13:1099–1106. 2008.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Popovik E and Haynes L: Survival and
mitogenesis of neuroepithelial cells are influenced by
noradrenergic but not cholinergic innervation in cultured embryonic
rat neopallium. Brain Res. 853:227–235. 2000.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chen L, Xin X, Eckhart AD, Yang N and
Faber JE: Regulation of vascular smooth muscle growth by alpha
1-adrenoreceptor subtypes in vitro and in situ. J Biol Chem.
270:30980–30988. 1995.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Faber JE, Yang N and Xin X: Expression of
alpha-adrenoceptor subtypes by smooth muscle cells and adventitial
fibroblasts in rat aorta and in cell culture. J Pharmacol Exp Ther.
298:441–452. 2001.PubMed/NCBI
|
|
34
|
Xin X, Yang N, Eckhart AD and Faber JE:
Alpha1D-adrenergic receptors and mitogen-activated protein kinase
mediate increased protein synthesis by arterial smooth muscle. Mol
Pharmacol. 51:764–775. 1997.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Bleeke T, Zhang H, Madamanchi N, Patterson
C and Faber JE: Catecholamine-induced vascular wall growth is
dependent on generation of reactive oxygen species. Circ Res.
94:37–45. 2004.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Hiramoto T, Satoh Y, Takishima K and
Watanabe Y: Induction of cell migration of neural progenitor cells
in vitro by alpha-1 adrenergic receptor and dopamine D1 receptor
stimulation. Neuroreport. 19:793–797. 2008.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Westhoff MA, Karpel-Massler G, Brühl O,
Enzenmüller S, La Ferla-Brühl K, Siegelin MD, Nonnenmacher L and
Debatin KM: A critical evaluation of PI3K inhibition in
Glioblastoma and Neuroblastoma therapy. Mol Cell Ther.
2(32)2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Guertin DA and Sabatini DM: Defining the
role of mTOR in cancer. Cancer Cell. 12:9–22. 2007.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Halacli SO and Dogan AL: FOXP1 regulation
via the PI3K/Akt/p70S6K signaling pathway in breast cancer cells.
Oncol Lett. 9:1482–1488. 2015.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Liu W, Ren H, Ren J, Yin T, Hu B, Xie S,
Dai Y, Wu W, Xiao Z, Yang X and Xie D: The role of
EGFR/PI3K/Akt/cyclinD1 signaling pathway in acquired middle ear
cholesteatoma. Mediators Inflamm. 2013(651207)2013.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Desiniotis A and Kyprianou N: Advances in
the design and synthesis of prazosin derivatives over the last ten
years. Expert Opin Ther Targets. 15:1405–1418. 2011.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ferrara N: Role of vascular endothelial
growth factor in regulation of physiological angiogenesis. Am J
Physiol Cell Physiol. 280:C1358–C1366. 2001.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Meyer RD and Rahimi N: Comparative
structure-function analysis of VEGFR-1 and VEGFR-2: What have we
learned from chimeric systems? Ann N Y Acad Sci. 995:200–207.
2003.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Meyer RD, Singh A, Majnoun F, Latz C,
Lashkari K and Rahimi N: Substitution of C-terminus of VEGFR-2 with
VEGFR-1 promotes VEGFR-1 activation and endothelial cell
proliferation. Oncogene. 23:5523–5531. 2004.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Clarke DE: Alpha adrenoceptor blockade in
the treatment of benign prostatic hyperplasia: Past, present and
future. Br J Urol. 82(167)1998.PubMed/NCBI
|
